

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)

Robert Levine, M.D.

Committees: ArthritisDrugs Advisory Committee

Meeting Date: April 12, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the safety and efficacy of New Drug Application (NDA) 21-389/21-772, proposed trade name, Arcoxia (etoricoxib), a non-steroidal, anti-inflammatory, cyclooxygenase-2 (COX-2) enzyme inhibitor, manufactured by Merck & Company, Inc., for the proposed indication of the relief of the signs and symptoms of osteoarthritis, I am eligible to receive waivers under 18 U.S.C. §208 (b)(3) and 21 U.S.C. §355(n)(4).

Type of Interest	Nature	Magnitude
Stock	Sponsor	Valued from \$25,001 to \$50,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waivers are not valid.

/s/
Signature of SGE

3/5/07
Date